Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 378-385

  Elaidi, Reza ^a,b   Harbaoui, A ^c   Beuselinck, B ^d   Eymard, J C ^e   Bamias, A ^f   De Guillebon, E ^g   Porta, C ^h   Vano, Y ⁱ   Linassier, C ^j   Debruyne, P R ^k,l   Gross Goupil, M ^c   Ravaud, A ^c   Aitelhaj, M ^a   Marret, G ^a   Oudard, S ^a,m  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Association Pour la Recherche de The rapeutiques Innovantes en Cance rologie   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Department of Oncology Centre Joliot Curie   (France)

^f UNIVERSITY OF ATHENS   (Greece)

^g University of Poitiers   (France)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁱ CENTRE ANTOINE LACASSAGNE   (France)

^j CHU BRETONNEAU   (France)

^k Kortrijk Cancer Center   (Belgium)

^l UNIVERSITY OF GREENWICH   (United Kingdom)

^m René Descarte University   (France)

more..

Author keywords

Kidney cancer; Mammalian target of rapamycin (mTOR); Sequence; Tyrosine kinase inhibitor

Indexed keywords

AXITINIB; EVEROLIMUS; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FUHRMAN GRADE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTATIC CLEAR CELL RENAL CELL CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SALVAGE THERAPY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84925304746     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu552     Document Type: Article

References (27)

1. NCCN Clinical Practice Guidelines in Oncology Guidelines. Kidney Cancer. Version 3. 2014.
2. Escudier B, Eisen T, Porta C et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii65-vii71.
3. Felici A, Bria E, Tortora G et al. Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. Expert Rev Anticancer Ther 2012; 12: 1545-1557.
4. Sonpavde G, Choueiri TK, Escudier B et al. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 2012; 61: 307-316.
5. Alimohamed N, Lee JL, Srinivas S et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2014; 12: e127-e131.
6. Albiges L, Choueiri T, Escudier B et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol 2015; 67: 100-110.
7. Calvo E, Gru¨nwald V, Bellmunt J. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. Eur J Cancer 2014; 50: 1321-1329.
8. Schmidinger M. Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. Am Soc Clin Oncol Educ Book 2014; e228-e238.
9. Motzer RJ, Barrios CH, Kim TM et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32: 2765-2772.
10. Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as secondline treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14: 552-562.
11. Hutson TE, Escudier B, Esteban E et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32: 760-767.
12. Al-Marrawi MY, Rini BI, Harshman LC et al. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGFtargeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013; 8: 203-209.
13. Escudier B, Michaelson MD, Motzer RJ et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014; 110: 2821-2828.
14. Calvani N, Morelli F, Chiuri V et al. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? Med Oncol 2013; 30: 578.
15. Procopio G, Sabbatini R, Porta C et al. Optimizing further treatment choices in short-and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2012; 12: 1089-1096.
16. Motzer RJ, Bukowski RM, Figlin RA et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113: 1552-1558.
17. Heng DY, Xie W, Regan MM et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14: 141-148.
18. Vickers MM, Choueiri TK, Rogers M et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factortargeted therapy. Urology 2010; 76: 430-434.
19. Iacovelli R, Carteni` G, Sternberg CN et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer 2013; 49: 2134-2142.
20. Park K, Lee JL, Park I et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol 2012; 29: 3291-3297.
21. Busch J, Seidel C, Erber B et al. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol 2013; 64: 62-70.
22. Busch J, Seidel C, Kempkensteffen C et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011; 60: 1163-1170.
23. Chen CC, Hess GP, Liu Z et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2012; 10: 256-261.
24. Wong MK, Yang H, Signorovitch JE et al. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin 2014; 30: 537-545.
25. Porta C, Paglino C, Imarisio I. Sorafenib rechallenge in metastatic renal cell carcinoma. BJU Int 2012; 110(6 Pt B): E235.
26. Kang YK, Ryu MH, Yoo C et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013; 14: 1175-1182.
27. Ferte´ C, Koscielny S, Albiges L et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. Eur Urol 2014; 65: 713-720.